Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)
Jakob Malsy, Luzia Veletzky, Janna Heide, Annette Hennigs, Ines Gil-Ibanez, Alexander Stein, Marc Lütgehetmann, Ulrich Rosien, Dorothea Jasper, Sven Peine, Jens Hiller, Friedrich Haag, Stefan Schmiedel, Samuel Huber, Sabine Jordan, Marylyn M. Addo, Julian Schulze zur Wiesch
Abstract
We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
Topics & Concepts
Convalescent plasmaCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusVirologyBetacoronavirusCoronavirus InfectionsDiseaseImmunologyInternal medicineInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19